Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2 Low Breast Cancers”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT06433804
What this trial is testing

Clinicopathological Parameters of HER2 Low Breast Cancers

Who this might be right for
HER2 Low Breast Cancers
Vardhman Mahavir Medical College And Safdarjung Hospital 70
Not applicableLooking for participantsNCT05831878
What this trial is testing

RC48-ADC in HER2-low Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
RenJi Hospital 36
Testing effectiveness (Phase 2)Study completedNCT00944047
What this trial is testing

Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression

Who this might be right for
Breast Cancer
University of Kansas Medical Center 32
Testing effectiveness (Phase 2)Looking for participantsNCT07198724
What this trial is testing

ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerHER2 Low Breast CarcinomaHER2-negative Breast Cancer+2 more
Kristina A. Fanucci 65
Not applicableStudy completedNCT06188494
What this trial is testing

UNFOLD Study Egypt

Who this might be right for
Breast Cancer
AstraZeneca 405
Large-scale testing (Phase 3)Looking for participantsNCT07543536
What this trial is testing

Megestrol Acetate for Fatigue Management in T-DXd Treated Breast Cancer

Who this might be right for
Advanced/Metastatic Breast CancerHER2+, Low, or Ultralow Advanced/Metastatic Breast Cancer
Sun Yat-sen University 132
Testing effectiveness (Phase 2)Looking for participantsNCT06207734
What this trial is testing

Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer

Who this might be right for
Breast Cancer
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest 120
Not applicableEnrolling By InvitationNCT07132749
What this trial is testing

NEPA in Patients With HER2-positive or HER2-low Advanced Breast Cancer Treated With T-DXd

Who this might be right for
Patients With HER2-positive Advanced Breast Cancer Treated With T-DXdPatients With HER2-low Advanced Breast Cancer Treated With T-DXd
Yeon Hee Park 100
Post-approval studies (Phase 4)Looking for participantsNCT07195344
What this trial is testing

Study Aiming to Compare the Plasma Exposure of the Payload (Free-DXd) in Patients Treated by T-DXd for Locally Advanced or Metastatic Breast Cancer According to Their BMI.

Who this might be right for
Locally Advanced or Metastatic Breast Cancers
Institut Claudius Regaud 210
Testing effectiveness (Phase 2)Looking for participantsNCT06665178
What this trial is testing

Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer

Who this might be right for
Breast Cancer
British Columbia Cancer Agency 20
Testing effectiveness (Phase 2)UnknownNCT02790580
What this trial is testing

Dose-dense Doxorubicin/Cyclophosphamide With Intermittent Low-dose Sunitinib in Breast Cancer Patients

Who this might be right for
Breast Cancer
National University Hospital, Singapore 98
Large-scale testing (Phase 3)WithdrawnNCT06585969
What this trial is testing

A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerER-positive Breast CancerLuminal B+2 more
Danish Breast Cancer Cooperative Group
Not applicableLooking for participantsNCT07331506
What this trial is testing

Validation of the Oncoliq Test for the Early Detection of Breast Cancer.

Who this might be right for
Breast Cancer DetectionBreast Cancer Early Stage Breast Cancer (Stage 1-3)Breast Cancer Female+5 more
Oncoliq US Inc 300
Testing effectiveness (Phase 2)Active Not RecruitingNCT05546268
What this trial is testing

Study of Oral MRT-2359 in Selected Cancer Patients

Who this might be right for
NSCLCSCLCHigh Grade Neuroendocrine Cancer+5 more
Monte Rosa Therapeutics, Inc 174
Testing effectiveness (Phase 2)Looking for participantsNCT06656624
What this trial is testing

Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel)

Who this might be right for
Advanced Breast Cancer
The First Affiliated Hospital with Nanjing Medical University 190
Testing effectiveness (Phase 2)Looking for participantsNCT06533826
What this trial is testing

TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

Who this might be right for
Breast CancerHER2-low Breast CancerMetastatic Breast Cancer+1 more
Ana C Garrido-Castro, MD 357
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07317778
What this trial is testing

Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer

Who this might be right for
Breast Cancer Early Stage Breast Cancer (Stage 1-3)HR Positive/HER2 Low Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 249
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07785856
What this trial is testing

Study of Trastuzumab Deruxtecan (T-DXd) in Combination With a RAGE Inhibitor in Patients With T-DXd-Resistant HER2-Positive or HER2-Low Metastatic Breast Cancer

Who this might be right for
T-dxd Resistant HER2-PositiveHER2 Low Metastatic Breast Cancer
The Methodist Hospital Research Institute 27
Large-scale testing (Phase 3)Ended earlyNCT05747794
What this trial is testing

Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination With Paclitaxel Chemotherapy

Who this might be right for
Breast Carcinoma
Immutep S.A.S. 72
Not applicableStudy completedNCT06168227
What this trial is testing

And Real-world Analysis of RC48-ADC in Patients With HER2-positive or HER2-low Expressing, Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
The First Affiliated Hospital with Nanjing Medical University 150
Next Page